Skip to main content
. 2022 Jul 14;150(3):594–603.e2. doi: 10.1016/j.jaci.2022.06.020

Fig 1.

Fig 1

The monocytes from certain patients with COVID-19 spontaneously produce ROSs. A, Fluorescence in monocytes from an HD that have been preincubated (DPI + LPS [---]) or not (LPS [___]) with the NADPH oxidase inhibitor DPI, exposed to DCFH-DA, and stimulated with LPS. As a negative control, we analyzed fluorescence in the same monocytes preincubated (DPI [...]) or not (None [gray dots]) with DPI and exposed to DCFH-DA. B, Fluorescence in monocytes from an HD (...), a non-ICU patient (non-ICU [___]), and an ICU patient (ICU [---]) exposed to DCFH-DA. C, Mean fluorescence intensity of ROS-producing monocytes from HDs, non-ICU patients (non-ICU), and ICU patients (ICU) exposed to DCFH-DA. One-way ANOVA test (P < .001). D, Mean fluorescence intensity of ROS-producing monocytes from ICU patients who did or did not survive. E, Identification of the classical, intermediate, and alternative monocyte subpopulations by flow cytometry. F, Fluorescence in CD14highCD16low (---), CD14+CD16+ (___), and CD14lowCD16high (...) monocytes from an ICU patient exposed to DCFH-DA. G, Percentages of CD14–CD16+ monocytes circulating in HDs, ICU patients, and non-ICU patients. One-way ANOVA test P = .032. H, Correlation between the proportions of intermediate and ROS-producing monocytes in ICU patients and non-ICU patients.